



19 April 2022

Summary of Licence Application DIR 191

International Flower Developments Pty Ltd has made an application under the *Gene Technology Act 2000* for Dealings involving the Intentional Release (DIR) of genetically modified organisms (GMOs) into the Australian environment.

Project Title	Commercial import and distribution of chrysanthemum genetically modified for altered flower colour ¹
Parent organism	Chrysanthemum (<i>Chrysanthemum x morifolium</i>)
Genetic modifications	
Introduced genes	Two introduced genes conferring blue or violet flower colour: <ul style="list-style-type: none">• <i>F3'5'H</i> - flavonoid 3',5'-hydroxylase gene from <i>Campanula medium</i>• <i>A3'5'GT</i> - anthocyanin 3',5'-glucosyltransferase gene from <i>Clitoria ternatea</i> Introduced marker gene: <ul style="list-style-type: none">• <i>nptII</i> – antibiotic resistance gene from <i>Escherichia coli</i>
Genetic modification method	<i>Agrobacterium tumefaciens</i> -mediated transformation
Number of lines	Five lines, known by the OECD unique identifiers NS-201806-5, NS-202201-4, NS-203701-1, NS-208133-5, and NS-212801-2
Principal purpose	Commercial import and distribution of cut flowers of GM chrysanthemum for ornamental use
Previous releases	The GM chrysanthemum lines are approved for cultivation in Colombia for the purpose of export of cut flowers. Cut flowers have been exported into the USA and Canada in shipment trials.
Proposed locations	Australia-wide
Proposed period of release	From issue of licence

Next steps

The Gene Technology legislation sets out what the Regulator must do, as well as what the Regulator can or must consider, before deciding whether or not to issue a licence for this application.

After consultation with the prescribed experts, agencies and authorities, the Regulator's staff will prepare a consultation version of the Risk Assessment and Risk Management Plan (RARMP) considering aspects of the application in accordance with the legislation.

The Regulator will seek comment on the consultation RARMP from the public, as well as a wide range of experts, agencies and authorities. These stakeholders will be invited to provide submissions on the risks to human health and safety, and on risks to the environment from the proposed release.

At this stage, the consultation RARMP is expected to be released for comment in **September 2022**.

¹ The title of the licence application submitted by International Flower Developments Pty Ltd is "Application for commercial import of flowers of five genetically modified chrysanthemum varieties; 2B, 3C, 4A, 5A and 8D".

After consultation, the Regulator's staff will finalise the RARMP, taking into account advice on relevant matters. The finalised RARMP will form the basis of the Regulator's decision whether or not to issue a licence. The consultation and final versions of the RARMP and associated documents will be available on the [OGTR website](#) when they are released.

Other information available from the [OGTR website](#):

- 'Questions and Answers' document for this application
- documents on genetic modification methods and selectable marker genes
- information on Australia's national scheme for regulation of gene technology and
- information on the DIR application process.

Please use the contact details below, if you

- would like a copy of the application. Please include the identifier DIR 191.
- have any questions about the application or the legislated evaluation process or
- wish to register on the mailing list.

The Office of the Gene Technology Regulator, MDP 54, GPO Box 9848, Canberra ACT 2601

Telephone: 1800 181 030

Email: ogtr@health.gov.au